OPTIMIZATION OF KINETICS IN A NOVEL GLUCOSE SENSOR
This Phase II SBIR involves the testing of a minimally invasive glucose sensor in vivo. Diabetes is an increasingly common lifelong disease and is associated with many complications. It is responsible for an estimated 10-15 percent of all health care expenditures. Effective treatment has been shown to prevent or delay many of the associated complications. The most common current treatments include diet, exercise, and self-monitoring of blood glucose (SMBG). An improvement to the current method would enable and encourage patients to monitor their glucose levels more closely and thus improve the general health and quality of life of the diabetic population.
The technology is based on a small optical sensor implant that is fluorescent
and detectable through the skin. We will finalize the sensor configuration to
obtain the fastest kinetics. Animal efficacy trials must be performed to bring
the sensor closer to clinical trials in humans. The performance of the sensor
will be studied in vivo to demonstrate that the sensor correlates with blood
glucose and follows glucose changes in tolerance tests. In vivo testing will be
performed to determine the recalibration interval, the reproducibility, and the
accuracy of the sensor. The lifetime and biocompatibility of the sensor will
also be determined.
Small Business Information at Submission:
SENSOR TECHNOLOGIES, INC.
SENSOR TECHNOLOGIES, INC. PARK NINE WEST SHREWSBURY, MA 01545
Number of Employees: